Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Press Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

Feb 19, 2019
Trovagene, Inc. Announces Reverse Stock Split
Reverse stock split intended to bring company into compliance with minimum bid price requirement for maintaining listing on Nasdaq Capital Market
Feb 14, 2019
Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference
Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerated
Jan 29, 2019
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
Trovagene receives "may proceed" notification from FDA for Phase 1b/2 trial of Onvansertib in combination with standard-of-care in patients with mCRC harboring KRAS mutations
Jan 23, 2019
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
Broad patent covers anti-androgen or androgen antagonist drugs, including combination treatment with Zytiga®, Xtandi® and Erleada® in multibillion-dollar market
Jan 15, 2019
Trovagene Announces Adjournment of Special Meeting of Stockholders Until February 12, 2019